Lancet[journal] 检索结果

1141. Russian attacks impacting maternal and child health.

作者: Ed Holt.
来源: Lancet. 2024年404卷10451期418-419页

1142. Cough syncope and recurrent respiratory papillomatosis.

作者: Christine Kim.;Anmol Baidwan.;Nelson Nicolasora.;Raed Alalawi.
来源: Lancet. 2024年404卷10451期474-475页

1143. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.

作者: Feixue Wei.;Damien Georges.;Irene Man.;Iacopo Baussano.;Gary M Clifford.
来源: Lancet. 2024年404卷10451期435-444页

Understanding the proportion of invasive cervical cancer (ICC) caused by different human papillomavirus (HPV) genotypes can inform primary (ie, vaccination) and secondary (ie, screening) prevention efforts that target specific HPV genotypes. However, using the global literature to estimate population attributable fractions (AFs) requires a methodological framework to address HPV genotype-specific causality from aggregated data. We aimed to estimate the proportion of ICC caused by different HPV genotypes at the global, regional, and national level.

1144. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply.

作者: Hanny Al-Samkari.;James B Bussel.;Yoshi Miyakawa.;Catherine M Broome.
来源: Lancet. 2024年404卷10451期434页

1145. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.

作者: Jeremy W Jacobs.;Garrett S Booth.;Laura D Stephens.;Christopher A Tormey.;Brian D Adkins.
来源: Lancet. 2024年404卷10451期433页

1146. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.

作者: Run-Wei Ma.;Kai Liu.;Juan Xie.
来源: Lancet. 2024年404卷10451期433-434页

1147. Waiting list models must account for departures before treatment - Authors' reply.

作者: Syed Ahmar Shah.;Chris Robertson.;Aziz Sheikh.
来源: Lancet. 2024年404卷10451期432-433页

1148. Waiting list models must account for departures before treatment.

作者: Richard M Wood.
来源: Lancet. 2024年404卷10451期431-432页

1149. Continuing challenges to health equity in Ireland.

作者: Desmond O'Neill.
来源: Lancet. 2024年404卷10451期431页

1150. Palliative care needs to adapt to counteract assisted suicide.

作者: Stefan Lorenzl.;Christiane Weck.;Sarah K Bublitz.;Andrea Egger-Rainer.;Clemens Brandl.
来源: Lancet. 2024年404卷10451期430-431页

1151. The role of the clinical virologist in pandemic responses.

作者: Jangu E Banatvala.;Peter Muir.;Will Irving.;Emma Meader.;Sandeep Ramalingam.;Mike Kidd.
来源: Lancet. 2024年404卷10451期430页

1152. Inequity in sustainable health today.

作者: Juan Garay.;Elham Kateeb.;Diana Zeballos.;Luis Eugenio Souza.; .
来源: Lancet. 2024年404卷10451期429-430页

1153. Bridging gaps in vertical transmission of HIV, syphilis, and hepatitis B in India.

作者: Sheikh Mohd Saleem.;Zulfqarul Haq.
来源: Lancet. 2024年404卷10451期428-429页

1154. Hajj 2024 heatwave: addressing health risks and safety.

作者: Abdulqadir J Nashwan.;Nasser Aldosari.;Abdelaziz Hendy.
来源: Lancet. 2024年404卷10451期427-428页

1155. A manifesto on improving cancer care in conflict-impacted populations.

作者: Tedros Adhanom Ghebreyesus.;Dina Mired.;Richard Sullivan.;Alexandra Mueller.;Andreas Charalambous.;Arman Kacharian.;Christos Tsagkaris.;Enrique Soto-Perez-de-Celis.;Henrik Grigoryan.;Julie Gralow.;Andre Ilbawi.;Khaled Ghanem.;Layth Mula-Hussain.;Bente Mikkelsen.;Mulugeta Yimer.;Nazik Hammad.;Stella Arakelyan.;Tezer Kutluk.;Zeena Salman.;Mark Lawler.;Gevorg Tamamyan.;Maria V Babak.;Jemma Arakelyan.
来源: Lancet. 2024年404卷10451期427页

1156. Digitising the ageing process with epigenetic clocks.

作者: Steve Horvath.;Eric J Topol.
来源: Lancet. 2024年404卷10451期423页

1157. Janine Mohamed: championing Indigenous health.

作者: Aarathi Prasad.
来源: Lancet. 2024年404卷10451期422页

1158. The rational design of cervical cancer prevention strategies.

作者: Mark Schiffman.;Silvia de Sanjose.
来源: Lancet. 2024年404卷10451期406-407页

1159. Medicalised female genital mutilation must stop.

作者: The Lancet.
来源: Lancet. 2024年404卷10451期405页

1160. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.

作者: Benjamin A Fisher.;Xavier Mariette.;Athena Papas.;Thomas Grader-Beck.;Hendrika Bootsma.;Wan-Fai Ng.;P L A van Daele.;Stephanie Finzel.;Ghaith Noaiseh.;Sergio Elgueta.;Josef Hermann.;Sara S McCoy.;Esen Akpek.;Arthur Bookman.;Monika Sopala.;Michela Montecchi-Palmer.;Wen-Lin Luo.;Cornelia Scheurer.;Wolfgang Hueber.; .
来源: Lancet. 2024年404卷10452期540-553页

Sjögren's disease is a chronic autoimmune disease with an unmet need for targeted therapies. The aim of the TWINSS study is to evaluate the safety and efficacy of iscalimab, a monoclonal antibody against CD40, in patients with active Sjögren's disease.

结果排序

文献格式

出版时间

出版类型

出版语言